Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | YWHAH | Q04917 | 3/20 | 0.41 |
| ▸ | PLA2G2A | P14555 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6890656 | 0.93 | THRB (0.37) | MAPTTHRBALDH1A1GAAPKM | |
| SCHEMBL6894722 | 0.93 | PLA2G2A (0.41) | MAPTTHRBALDH1A1GAAPKM | |
| SCHEMBL6895778 | 0.92 | PLA2G2A (0.45) | MAPTALDH1A1PLA2G2A | |
| SCHEMBL6892310 | 0.92 | FAAH (0.41) | MAPTTHRBALDH1A1YWHAH | |
| SCHEMBL6896161 | 0.91 | HSP90AA1 (0.40) | MAPTTHRBALDH1A1GAAPKM | |
| SCHEMBL6895041 | 0.91 | MAPT (0.45) | MAPTTHRBALDH1A1GAAKMT2A | |
| SCHEMBL27562999 | 0.91 | KDM4E (0.39) | MAPTTHRBALDH1A1GAAKMT2A | |
| SCHEMBL6895034 | 0.90 | L3MBTL1 (0.43) | MAPTALDH1A1GAAKMT2AMEN1 | |
| SCHEMBL6897629 | 0.90 | POLB (0.36) | MAPTTHRB | |
| SCHEMBL6893995 | 0.90 | SLC6A2 (0.38) | THRBALDH1A1KMT2AMEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0952149-A2 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | ELI LILLY AND COMPANY (US) | 1999-10-27 | — | — | EP | claimed |
| EP-0952149-B1 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | LILLY CO ELI (US) | 2004-06-09 | — | — | EP | disclosed |
| US-6713645-B1 | INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK | ELI LILLY AND COMPANY | 2004-03-30 | — | — | US | disclosed |
| US-6177440-B1 | THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR | ELI LILLY AND COMPANY | 2001-01-23 | — | — | US | disclosed |
| CN-1240210-A | Substituted tricyclic compound | LILLY CO ELI (US) | 2000-01-05 | — | — | CN | disclosed |
| EP-0952149-A2 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | ELI LILLY AND COMPANY (US) | 1999-10-27 | — | — | EP | disclosed |